Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-203-2C in Relapsed or Refractory Acute Myeloid Leukemia
NCT02204085Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Sep 2014
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of GO-203-2C in acute myeloid leukemia (AML), sponsored by Beth Israel Deaconess Medical Center. Started Sep 2014; status: completed.
02
Drugs
GO-203-2C
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02204085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204085.